Evidence map›Paper›PMID 35619698›Full record

ArticleFrontiers in immunology2022

Comprehensive Analysis of Ferroptosis- and Immune-Related Signatures to Improve the Prognosis and Diagnosis of Kidney Renal Clear Cell Carcinoma.

Xiao-Liang Xing, Yan Liu, Jiheng Liu, Huanfa Zhou, Huirong Zhang, Qi Zuo, Ping Bu, Tong Duan, Yan Zhou, Zhiquan Xiao

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiao-Liang XingDepartment of General Medicine, University of South China affiliated Changsha Central Hospital, Changsha, China.
Yan LiuDepartment of General Medicine, University of South China affiliated Changsha Central Hospital, Changsha, China.
Jiheng LiuDepartment of Emergency, First Hospital of Changsha, Changsha, China.
Huanfa ZhouDepartment of General Medicine, University of South China affiliated Changsha Central Hospital, Changsha, China.
Huirong ZhangDepartment of General Medicine, University of South China affiliated Changsha Central Hospital, Changsha, China.
Qi ZuoDepartment of Emergency, First Hospital of Changsha, Changsha, China.
Ping BuDepartment of General Medicine, University of South China affiliated Changsha Central Hospital, Changsha, China.
Tong DuanDepartment of Emergency, First Hospital of Changsha, Changsha, China.
Yan ZhouDepartment of Emergency, First Hospital of Changsha, Changsha, China.
Zhiquan XiaoDepartment of General Medicine, University of South China affiliated Changsha Central Hospital, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Almost 40% of patients with kidney renal clear cell carcinoma (KIRC) with advanced cancers eventually develop to metastases, and their 5-year survival rates are approximately 10%. Aberrant DNA methylations are significantly associated with the development of KIRC. The aim of our present study was to identify suitable ferroptosis- and immune-related (FI) biomarkers correlated with aberrant methylations to improve the prognosis and diagnosis of KIRC. Methods: ChAMP and DESeq2 in R (3.6.2) were used to screen the differentially expressed methylation probes and differentially expressed genes, respectively. Univariate and multivariate Cox regression were used to identify the overall survival (OS)-related biomarkers. Results: We finally identified five FI biomarkers ( Conclusion: Our present study suggested that these five FI-DEGs (

Indexed as

Carcinoma, Renal CellFerroptosisKidney NeoplasmsBiomarkers, TumorHumansKidneyPrognosisBiomarkers, TumordiagnosisferroptosisimmuneKIRCmethylationprognosis

Identifiers

PMID35619698
PMCPMC9128788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.